💊scientific experiment protocol

Pump.Science Longevity Testing Protocol (Simple Overview)

This document explains our three‑stage pipeline for evaluating compounds that may extend lifespan and improve healthspan. Each stage builds on the previous one, starting with short‑lived invertebrates and progressing to mammals.

---

Stage 1 – C. elegans Lifespan Assay

Item	Details
Contract Lab	Ora Biomedical
Model Organism	Caenorhabditis elegans (wild‑type N2)
Group Size	60 worms / compound vs 60 worms / vehicle control
Primary Endpoint	Median & maximum lifespan
Runtime	Up to 8 weeks (culture → final death event)
Data Delivery	Experiment is run first; full video & data are streamed retrospectively once complete

Why this matters C. elegans provide a rapid first screen for pro‑longevity effects before investing in more complex organisms.

---

Stage 2 – Drosophila (Fly) Health & Lifespan Assay

Item	Details
Contract Lab	Tracked Biotechnologies
Model Organism	Drosophila melanogaster
Group Size	45 flies / compound vs 45 flies / control
Primary Endpoints	• Lifespan• Movement metrics (speed & total distance) • Negative geotaxis (climbing latency)
Lead Time	≈ 10 days to culture and load arenas
Runtime	≈ 70 days total
Data Delivery	Continuous streaming video + rolling data uploads

Why this matters Motor performance (geotaxis) and spontaneous activity act as surrogates for overall health, revealing functional benefits beyond survival alone.

---

Stage 3 – Mouse Lifespan & Functional Assay

Item	Details
Contract Lab	VivoArchitect
Model Organism	C57BL/6 mice
Group Size	20 mice / compound vs 20 mice / control
Primary Endpoint	Overall survival (lifespan)
Supplementary Tests*	Open Field, Rotarod, Y‑Maze, Elevated Plus Maze, Hanging Test, Grip Strength, Automated Gender Recognition
Health Monitoring	Body weight, rectal temperature, CBC, plasma safety biomarkers
Sourcing	Mice purchased from licensed SPF vendor (C57BL/6, 6‑8 weeks old)

*Functional assays are selected case‑by‑case, driven by the compound’s proposed mechanism.

---

Stage 4 – Human Wearable‑Based Double‑Blind Study

Item	Details
Study Type	Randomised, placebo‑controlled, double‑blind
Participants	~30 healthy adults per arm (exact N defined per protocol)
Primary Endpoints	Wearable‑derived endpoints, i.e. VO₂max, resting heart rate, sleep efficiency, etc.
Secondary Endpoints	Heart‑rate variability, activity level, other validated wearable biomarkers
Runtime	12 weeks
Data Delivery	De‑identified wearable data streamed to an open dashboard in near‑real time

Why this matters Human data confirms translatability and identifies early signals of safety & efficacy before larger trials.

---

• Compound Dosing – Dosing regimens are set in consultation with each CRO and compound submitter.

For detailed, peer‑reviewable methodology, refer to our preprint

---

Last updated: 2025‑07‑06